This CAR programs tumor-specific T cells to convert TGF-β from an immunosuppressive agent into an immunostimulatory one, thereby reshaping the immunosuppressive TME and enhancing antitumor responses in GBM 102. This evidence concerns the gene TGFB1 and neoplasm.